North Island Tour Of Award-Winning Show Brings Immersive Theatre To Regional Audiences
Red Scare Theatre Company is bringing its award-winning Immersive production Before We Slip Beneath the Sea around the North Island this July. Written and directed by the company's artistic director Cassandra Tse, Before We Slip Beneath the Sea follows inhabitants of the fictional island off the north coast called Eglantyne. Here, the local community have gathered for the last time in the wake of an impending evacuation due to rising sea levels. When one community member decides to take a stand against the evacuation, the community is divided, long-buried tensions come to the fore, and everyone must decide how to cope with change, loss and forces far greater than themselves.
Red Scare will be swapping out traditional theatre spaces for community halls for this Immersive show, which aims to break the usual separation between audience and actors. 'Immersive theatre is different from traditional theatre in that the audience are actually inside the storyworld, rather than sitting outside and looking in,' says Tse. 'In Before We Slip Beneath the Sea, audiences have the freedom to choose their own path to navigate the story, encountering and interacting with different characters. It's a huge challenge, but there's also so much potential for exciting storytelling.' Audience members can choose to eavesdrop on budding romances, intervene in family disputes, or even help out in the kitchen.
The play was awarded Winner of Best Play by a Woman Playwright and overall Runner-Up at the 2024 Adam NZ Play Awards. The production's 2024 Wellington season was called 'a hauntingly beautiful portrayal of human relationships' (Elliott Lam, Wellyott) and 'an absorbing and salutary experience' (John Smythe, Theatreview).
'In an Immersive show, the actors have to be able to switch back and forth between scripted scenes and improvisation with ease, allowing audiences to engage with the characters while never losing track of the story. It's a really difficult ask, so I'm lucky that I'm working with such a talented group of actors,' says Tse. The cast consists of a mix of returnees from Red Scare Theatre shows like Charlie Potter (Gutenberg! The Musical), Ralph Johnson (Four Nights in the Green Barrow Pub) and performers collaborating with Red Scare for the first time (Hannah McKenzie Doornebosch, Craig Geenty, Megan Connolly, Helen Jones and Billie Deganutti).
'This show lets each audience member really take control of their own relationship to the play – whether they want to join the characters in conversation, hang back and eavesdrop, or simply float around the hall absorbing the atmosphere,' Tse says. 'My hope is that whether or not audience members love or hate participatory theatre, they come away from this show feeling like they're a part of the Eglantyne community.'
Before We Slip Beneath the Sea will be travelling to Auckland, Hamilton, Rotorua, Napier, Palmerston North and Carterton. Tickets and performance dates for the show are available through Eventfinda.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South Wales Argus
26 minutes ago
- South Wales Argus
Rogerstone: Four-bed detached house in Alcan Grove for sale
The property, listed by Davis & Sons, boasts a large living room, study, utility room, conservatory, and a spacious kitchen diner. There is also an en-suite attached to the master bedroom, and another to the second bedroom. The property also features an entrance hall, utility room, and a downstairs WC. The conservatory (Image: Davis & Sons) The property has a large evergreen rear garden, a spacious lawn area, and a patio seating area. There is also a double driveway and garage to the front, providing ample off-street parking. The house is situated in a quiet residential area, close to local amenities, schools, and transport links. Rogerstone, a suburban village in Newport, blends historic charm with modern convenience. One of the bedrooms (Image: Davis & Sons) It offers well-regarded schools, green spaces like the Fourteen Locks Canal Centre, and regular rail links to Newport and Cardiff via Rogerstone station. With easy access to the M4, it is a popular choice for families and commuters seeking a strong community feel with excellent transport connections. The agency states: "This property is not to be missed." To arrange a viewing, contact the Newport head office or reach out via email.
Yahoo
27 minutes ago
- Yahoo
Alex Pereira: Focus on Magomed Ankalaev rematch, not heavyweight move
NEW YORK—Fans clamoring for Alex Pereira to move to heavyweight are going to have to wait a bit longer. Pereira dropped the UFC light heavyweight title to Magomed Ankalaev in the main event of UFC 313 in March. With the heavyweight division up in the air, Jon Jones saying multiple times he's not interested in fighting right now, and interim champ Tom Aspinall looking for an opponent, 'Poatan' would be a popular choice to flip one of the UFC's thinner divisions upside down. Advertisement That time is not now, however, as Pereira has his sights set on a fall return to avenge his loss to Ankalaev. 'Anywhere around the timeframe [of] September, October, November, for me it makes no difference, I want to fight,' Pereira told MMA Fighting at Fanatics Fest. 'My focus right now is fighting Ankalaev... get my belt back, and then we see what happens after.' Pereira has accomplished so much in so little time that the opportunity to win a third divisional title seems like a reasonable goal and request. Right now, Pereira hopes the heavyweight division can get moving again in an entertaining way, but he has his own boxes to check. Advertisement 'Let those guys kill each other in that weight class,' Pereira said. 'Right now I'm just focusing on light heavyweight.' More from
The Independent
27 minutes ago
- The Independent
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
